Insulin Oral Drops Ready for Next Stage of Clinical Trials

With the pre-clinical trial data providing exciting results, the management is in discussions with one of the biggest pharma companies in the world to out-license the oral delivery of Insulin as a first step.

Transgene Biotek Ltd. said on Wednesday that it has completed the development of oral delivery of Insulin collaboration with the Pharmacology Division headed by Dr. Prakash V Diwan at the Indian Institute of Chemical Technology, Hyderabad. The pre-clinical trials on the oral delivery of Insulin have demonstrated exciting results, Transgene Biotek said in a statement. The drug is to be administered in liquid form as oral drops.

The new invention is a boon to the diabetic population showing not only the reduction of blood glucose levels compatible to that of the injectable Insulin but also the clinically significant plasma Insulin levels lasting up to 24 hours, Transgene Biotek said. This is a significant achievement since the sustainable plasma Insulin levels up to 24 hours implies the possibility of reducing the frequency of Insulin doses resulting in high patient complaince and better management of Diabetes, it added.

With the pre-clinical trials providing the necessary data, the management has initiated steps to take it to the next stage of clinical trials in India and Europe simultaneously, Transgene Biotek said.

===============================
Start your own walking program.
New StepTracker Available at special prices. See the results of the Step Program Study.
https://www.diabetesincontrol.com/programs/steps/index.shtml
Purchase your own pedometers and receive the Steps To Health Program at no charge. https://www.rx4betterhealth.com/steptracker/
The Only Pedometer On The Market That Comes With A Program For Success!

===============================

DID YOU KNOW: Depression Increased Mortality in Patients with Type 2: Both major and minor depression were found to be associated with significantly higher mortality in patients with type 2 diabetes compared with nondepressed patients with diabetes alone. The study assessed whether patients with comorbid minor and major depression and type 2 diabetes had a higher mortality rate over a 3-year period compared with patients with diabetes alone. In conclusion, in a population-based sample of patients with type 2 diabetes, both major depression and minor depression were associated with increased mortality rates over a 3-year period. Diabetes Care. 2005 Nov;28(11):2668-72.